Chemical Formula: C16H21NO2

Chemical Formula C16H21NO2

Found 59 metabolite its formula value is C16H21NO2

Propranolol

[2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine

C16H21NO2 (259.1572206)


Propranolol is a widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. --PubChem; Propranolol is a highly lipophilic drug achieving high concentrations in the brain. The duration of action of a single oral dose is longer than the half-life indicates and may be up to 12 hours, if the single dose is high enough (e.g. 80 mg). Effective plasma concentrations are between 10-100 ng/mL. -- Wikipedia; It was the first successful beta blocker developed. Propranolol is commonly marketed by Wyeth under the trade name Inderal. A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. --PubChem; Propranolol is a highly lipophilic drug achieving high concentrations in the brain. The duration of action of a single oral dose is longer than the half-life indicates and may be up to 12 hours, if the single dose is high enough (e.g. 80 mg). Effective plasma concentrations are between 10-100 ng/mL. -- Wikipedia; It was the first successful beta blocker developed. Propranolol is commonly marketed by Wyeth under the trade name Inderal. [HMDB] C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 171 KEIO_ID P192; [MS2] KO009171 KEIO_ID P192 Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3]. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3]. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].

   

HQNO

2-Heptyl-4-hydroxyquinoline N-oxide

C16H21NO2 (259.1572206)


HQNO, secreted by P. aeruginosa, is a potent electron transport chain inhibitor with a Kd of 64 nM for complex III[1]. HQNO is a potent inhibitor of mitochondrial NDH-2 in many species[2]. HQNO, secreted by P. aeruginosa, is a potent electron transport chain inhibitor with a Kd of 64 nM for complex III[1]. HQNO is a potent inhibitor of mitochondrial NDH-2 in many species[2].

   

2-Heptyl-3-hydroxy-quinolone

2-Heptyl-3-hydroxy-4(1H)-quinolone

C16H21NO2 (259.1572206)


   

Norbutorphanol

(1S,9R,10S)-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-triene-4,10-diol

C16H21NO2 (259.1572206)


Norbutorphanol belongs to the family of Morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.

   

Norchalciporyl propionate

(5Z)-6-(2-Methyl-2H-azepin-7-yl)hexa-3,5-dien-1-yl propanoic acid

C16H21NO2 (259.1572206)


Norchalciporyl propionate is found in mushrooms. Norchalciporyl propionate is a pungent principle from fruit-bodies of the edible mushroom (Chalciporus piperatus

   

Ramelteon

(S)-N-(2-(1,6,7,8-Tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide

C16H21NO2 (259.1572206)


Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CH - Melatonin receptor agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Nortilidine

Ethyl 2-(methylamino)-1-phenylcyclohex-3-ene-1-carboxylic acid

C16H21NO2 (259.1572206)


   
   

3alpha-Phenylacetoxytropane

3alpha-Phenylacetoxytropane

C16H21NO2 (259.1572206)


   
   
   

Pyo II

2-n-Heptyl-4-hydroxyquinoline N-oxide

C16H21NO2 (259.1572206)


HQNO, secreted by P. aeruginosa, is a potent electron transport chain inhibitor with a Kd of 64 nM for complex III[1]. HQNO is a potent inhibitor of mitochondrial NDH-2 in many species[2]. HQNO, secreted by P. aeruginosa, is a potent electron transport chain inhibitor with a Kd of 64 nM for complex III[1]. HQNO is a potent inhibitor of mitochondrial NDH-2 in many species[2].

   
   

PQS

2-Heptyl-3-hydroxyl-4(1H)-quinolone

C16H21NO2 (259.1572206)


   

phenylacetoxytropane

phenylacetoxytropane

C16H21NO2 (259.1572206)


   
   
   

1-Methyl-8-methoxy-2-pentylquinolin-4(1H)-one

1-Methyl-8-methoxy-2-pentylquinolin-4(1H)-one

C16H21NO2 (259.1572206)


   

(+)-lycopladine A|lycopladine A

(+)-lycopladine A|lycopladine A

C16H21NO2 (259.1572206)


   

(+)-grandisine D|(5S)-6-((S)-1,2,3,5,6,8a-hexahydroindolizine-8-carbonyl)-5-methylcyclohex-2-enone|grandisine D

(+)-grandisine D|(5S)-6-((S)-1,2,3,5,6,8a-hexahydroindolizine-8-carbonyl)-5-methylcyclohex-2-enone|grandisine D

C16H21NO2 (259.1572206)


   
   
   
   
   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methylacetamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methylacetamide

C16H21NO2 (259.1572206)


   

dodeca-4-keto-2E-ene-8,10-diynoic acid isobutylamide

dodeca-4-keto-2E-ene-8,10-diynoic acid isobutylamide

C16H21NO2 (259.1572206)


   

Pseudoepiisoelaeocarpiline

Pseudoepiisoelaeocarpiline

C16H21NO2 (259.1572206)


   

propranolol

propranolol

C16H21NO2 (259.1572206)


A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents CONFIDENCE standard compound; INTERNAL_ID 1248; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7445; ORIGINAL_PRECURSOR_SCAN_NO 7444 CONFIDENCE standard compound; INTERNAL_ID 1248; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7453; ORIGINAL_PRECURSOR_SCAN_NO 7452 CONFIDENCE standard compound; INTERNAL_ID 1248; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7471; ORIGINAL_PRECURSOR_SCAN_NO 7467 CONFIDENCE standard compound; INTERNAL_ID 1248; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7471; ORIGINAL_PRECURSOR_SCAN_NO 7469 CONFIDENCE standard compound; INTERNAL_ID 1248; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7478; ORIGINAL_PRECURSOR_SCAN_NO 7476 CONFIDENCE standard compound; INTERNAL_ID 1248; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7485; ORIGINAL_PRECURSOR_SCAN_NO 7484 CONFIDENCE standard compound; INTERNAL_ID 1108 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 61 CONFIDENCE standard compound; INTERNAL_ID 8556 Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3]. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3]. Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].

   

Ramelteon

N-{2-[(8S)-1H,2H,6H,7H,8H-indeno[5,4-b]furan-8-yl]ethyl}propanamide

C16H21NO2 (259.1572206)


N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CH - Melatonin receptor agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

2-nonylquinoline-3,4-diol:Series 3 HAQ C9

2-nonylquinoline-3,4-diol:Series 3 HAQ C9

C16H21NO2 (259.1572206)


   

Pseudomonas quinolone signal

Pseudomonas quinolone signal

C16H21NO2 (259.1572206)


   

2-heptyl-3-hydroxy 4-quinolone

2-Heptyl-3-hydroxy-4(1H)-quinolinone

C16H21NO2 (259.1572206)


   

Norchalciporyl propionate

(3E,5Z)-6-(2-methyl-2H-azepin-7-yl)hexa-3,5-dien-1-yl propanoate

C16H21NO2 (259.1572206)


   

Norbutorphanol

(1S,9R,10S)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4,10-diol

C16H21NO2 (259.1572206)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids

   

2-(2-BENZOFURANYL)-4-TERT-BUTYL-MORPHOLINE

2-(2-BENZOFURANYL)-4-TERT-BUTYL-MORPHOLINE

C16H21NO2 (259.1572206)


   

Nortilidine

3-Cyclohexene-1-carboxylic acid, 2-(methylamino)-1-phenyl-, ethyl ester, (1R,2S)-rel-

C16H21NO2 (259.1572206)


   

Ethyl 3-benzyl-2-cyano-3-methylpentanoate

Ethyl 3-benzyl-2-cyano-3-methylpentanoate

C16H21NO2 (259.1572206)


   

2-methyloxirane,oxirane,prop-2-enenitrile,styrene

2-methyloxirane,oxirane,prop-2-enenitrile,styrene

C16H21NO2 (259.1572206)


   

Benzyl (2S,3aR,7aS)-octahydro-1H-indole-2-carboxylate

Benzyl (2S,3aR,7aS)-octahydro-1H-indole-2-carboxylate

C16H21NO2 (259.1572206)


   

trans-4-(5-pentyl-1,3-dioxan-2-yl)benzonitrile

trans-4-(5-pentyl-1,3-dioxan-2-yl)benzonitrile

C16H21NO2 (259.1572206)


   

4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester

4-phenyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester

C16H21NO2 (259.1572206)


   

3-indoxyl caprylate

3-indoxyl caprylate

C16H21NO2 (259.1572206)


   

benzyl 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylate

benzyl 2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylate

C16H21NO2 (259.1572206)


   

Benzyl (2S,3aR,7aS)-octahydroindole-2-carboxylate hydrochloride

Benzyl (2S,3aR,7aS)-octahydroindole-2-carboxylate hydrochloride

C16H21NO2 (259.1572206)


   

1H-Indole, 1-[2-(1,3-dioxolan-2-yl)ethyl]-2,3-dihydro-3,3-dimethyl-2-methylene-

1H-Indole, 1-[2-(1,3-dioxolan-2-yl)ethyl]-2,3-dihydro-3,3-dimethyl-2-methylene-

C16H21NO2 (259.1572206)


   

ETHYL 2-(1-BENZYLPIPERIDIN-4-YLIDENE)ACETATE

ETHYL 2-(1-BENZYLPIPERIDIN-4-YLIDENE)ACETATE

C16H21NO2 (259.1572206)


   
   

2-(2-Cyanoethyl)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran

2-(2-Cyanoethyl)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran

C16H21NO2 (259.1572206)


   

Dexpropranolol

Dexpropranolol

C16H21NO2 (259.1572206)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

(2S)-2-hydroxy-5-methyl-1-(1-methylindol-3-yl)hexan-3-one

(2S)-2-hydroxy-5-methyl-1-(1-methylindol-3-yl)hexan-3-one

C16H21NO2 (259.1572206)


   

(2S)-2-hydroxy-4-methyl-1-(1-methylindol-3-yl)hexan-3-one

(2S)-2-hydroxy-4-methyl-1-(1-methylindol-3-yl)hexan-3-one

C16H21NO2 (259.1572206)


   

3-Phenylacetyl-5-pentyl-2-isoxazoline

3-Phenylacetyl-5-pentyl-2-isoxazoline

C16H21NO2 (259.1572206)


   

Methyl 2-isopropyl-3-methyl-5-phenyl-1-pyrroline-4-carboxylate (3,4-trans-4,5-cis)

Methyl 2-isopropyl-3-methyl-5-phenyl-1-pyrroline-4-carboxylate (3,4-trans-4,5-cis)

C16H21NO2 (259.1572206)


   

(R)-(+)-propranolol

(R)-(+)-propranolol

C16H21NO2 (259.1572206)


   

ethyl 2-(methylamino)-1-phenylcyclohex-3-ene-1-carboxylate

ethyl 2-(methylamino)-1-phenylcyclohex-3-ene-1-carboxylate

C16H21NO2 (259.1572206)


   

(1R,2S)-nortilidine

(1R,2S)-nortilidine

C16H21NO2 (259.1572206)


An ethyl 2-(methylamino)-1-phenylcyclohex-3-ene-1-carboxylate that is ent-dextilidine in which one of the methyl groups attached to the nitrogen is replaced by hydrogen. ent-Dextilidine is metabolised to (1R,2S)-nortilidine by the liver.

   

(1S,2R)-nortilidine

(1S,2R)-nortilidine

C16H21NO2 (259.1572206)


A ethyl 2-(methylamino)-1-phenylcyclohex-3-ene-1-carboxylate that is dextilidine in which one of the methyl groups attached to the nitrogen is replaced by hydrogen. Dextilidine is a prodrug for (1S,2R)-nortilidine, being metabolised to it by the liver.